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Determination of ramipril in human plasma and its
fragmentation by UPLC-Q-TOF-MS with positive 
electrospray ionization
This report presents the application of ultra-performance 
liquid chromatography coupled to quadrupole time-of- 
-ﬂ ight mass spectrometry with positive electrospray ion-
ization, to determine ramipril in human plasma. First, the 
proteins in human plasma were precipitated using acetoni-
trile, then the supernatant was extracted by ethyl acetate at 
pH 3 and ﬁ nally, the extract was analyzed using a UPLC-Q-
TOF-MS system. The method was validated and the coeﬃ  -
cient of determination (R2) was > 0.999, the lower limit of 
quantiﬁ cation (LLOQ) was 0.5 ng mL–1. Precision, recovery 
and stability were determined for three diﬀ erent concen-
trations of ramipril. RSD for this method ranged from 3.3 to 
8.6 %. The intra-day mean recovery was from 65.3 to 97.3 %. 
In addition, the fragmentation of ramipril was studied. Due 
to high resolution of the spectrometer, it was possible to 
measure fragment masses accurately and determine their 
molecular and chemical formulas with high accuracy.
Keywords: ramipril, UPLC-Q-TOF-MS, fragmentation path-
way
Ramipril is a speciﬁ c angiotensin-converting enzyme (ACE) inhibitor. The drug is 
applied for all grades of hypertension (1). Ramipril is chemically designated as (2S,3aS,6aS)-
1-[(2S)-2-[[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]propanoyl]-3,3a,4,5,6,6a-hexahy-
dro-2H-cyclopenta[d]pyrrole-2-carboxylic acid. The major metabolite of ramipril is rami-
prilat. Ramiprilat is formed by ester hydrolysis.
Ramipril was analyzed by various methods, such as spectrophotometry (2–4), atomic 
absorption (2), spectroﬂ uorimetry (3), capillary electrophoresis (5), HPLC with a photo-
diode array detector (6), supercritical ﬂ uid chromatographic technique (7), gas chromatog-
raphy-mass spectrometry (GC-MS) (8), liquid chromatography-mass spectrometry (LC-
MS) (9–17). However, some of these methods were characterized by high limit of detection 
or their results provided li le information about fragmentation of the compound. Solid 
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phase extraction was most o en used for isolation of ramipril from human plasma (8–11, 
13, 16). Ramipril can be also successfully isolated by liquid-liquid extraction with a 70/30 
(V/V) diethyl ether/dichloromethane mixture (1), ethyl acetate (15), or a er protein pre-
cipitation with methanol (17).
Broecker et al. (18) identiﬁ ed ramipril using ultra-performance liquid chromatography 
coupled to quadrupole time-of-ﬂ ight tandem mass spectrometry (UPLC-Q-TOF-MS) but 
have not investigated its fragmentation pathway. UPLC-Q-TOF-MS is more selective and 
sensitive than the commonly employed techniques such as single quadrupole mass spec-
trometry due to its high accuracy of mass determination. This technique allows to iden-
tify metabolites and products of drug degradation (19–22). This novel technique can be 
used for accurate measurement of compounds and their fragments.
The objective of this paper was to develop a method for determining ramipril in hu-
man plasma and to study its fragmentation. In addition, we propose the possible pathway 
of ramipril fragmentation based on MS/MS spectra.
EXPERIMENTAL
Chemicals and reagents
Water, acetonitrile, methanol (Chromasolv® LC-MS, Fluka, Germany), ramipril 
(HPLC, Sigma-Aldrich, Germany) ethyl acetate (HPLC grade, AppliChem, Germany), for-
mic acid (Fluka), diazepam-D5 (Cerilliant, USA) and ammonium chloride (Sigma-Aldrich, 
Germany) were used.
Instrumentation
Chromatographic analysis was performed using an ultra-performance liquid chro-
matograph (UPLC 1290, Agilent Technologies, Germany). The separation was done em-
ploying a Poroshell 120 EC-C18 column 3.0 × 100 mm; 2.7 µm (Agilent Technologies, USA) 
with a thermostat at 40 °C. A mixture of 0.1 % formic acid in water (A) and 0.1 % formic 
acid in acetonitrile (B) was used as a mobile phase. Gradient elution was carried out at a 
constant ﬂ ow of 0.4 mL min–1. The following gradient was applied: 0 min 95 % A (5 % B), 
0–5 min 30 % A (70 % B), 5–7 min 0 % A (100 % B) and then 7–8.5 min 100 % A (0 % B). 
Return to the starting gradient composition (95 % A and 5 % B) was performed at 4 min. 
The injected volume was 10 µL.
Detection of the investigated compounds was achieved using a quadrupole coupled 
to time-of-ﬂ ight analyzer (Q-TOF-MS 6540, Agilent Technologies, USA). The spectrometer 
was equipped with an ESI Jet Stream source; identiﬁ cation and determination of the inves-
tigated drug was carried out in the SCAN mode. Operating spectrometer parameters are 
presented in Table I.
Stock solutions, blank material and calibration standards
Standard solutions of ramipril and diazepam-D5 were prepared in methanol. All solu-
tions were stored at –20 °C.
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Blank samples of human plasma were derived from the patients of the Chair and De-
partment of Gastroenterology with Endoscopic unit, Medical University of Lublin, Poland. 
Study design was approved by the Bioethics Commi ee, Medical University of Lublin.
Blank samples of human plasma were screened prior to spiking in order to ensure that 
they were free from ramipril. Standard curves were prepared by spiking blank human 
plasma to yield ﬁ nal concentrations of 0.5, 1, 5, 10, 25, and 50 ng mL–1 for ramipril.
Sample preparation
Human plasma (200 µL) was transferred to 1.5-mL Eppendorf tube adding 20 µL in-
ternal standard (diazepam-D5, concentration 250 ng mL–1). Protein precipitation was car-
ried out adding 200 µL of acetonitrile. A er vortex mixing for 1 min and centrifugation for 
15 min at 20627 g at 5 °C, all of the supernatant was transferred to 12-mL test tubes, subse-
quently adding 200 µL of buﬀ er (0.5 mol L–1 ammonium chloride – pH 3). Liquid-liquid 
extraction with ethyl acetate (2 mL) was carried out for 20 min. Samples were centrifuged 
at 5039 g and the organic phase (1.7 mL) was transferred to 2-mL Eppendorf tube and 
evaporated to dryness under a stream of nitrogen (at 45 °C). The extract was dissolved in 
25 µL of 1:1 acetonitrile/water, V/V) mixture, transferred to silanized glass insert and ana-
lyzed by UPLC-Q-TOF-MS.
Validation
Linearity. – Linearity was evaluated by the analysis of ramipril standard solutions in 
ﬁ nal concentrations of 0.5, 1, 5, 10, 25 and 50 ng mL–1.
Table I. Spectrometer operating parameters








OCT 1RF Vpp – 750
Ionization ESI jet stream (positive ions)
Source
Gas temp. – 300 °C
Drying gas – 10 L min–1
Nebulizer – 241.3 kPa (N2)
Sheath gas temp. – 400 °C
Sheath gas ﬂ ow – 12 L mi n–1
Acquisition rate/time
Rate – 5 spectra s–1
Time – 200 ms per spectrum
Mass range (m/z) 100–1000
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Precision. – Five repeats of spiked samples at 0.5, 5 and 25 ng mL–1 were analyzed with 
calibration samples in one batch. Relative standard deviation was calculated for each con-
centration.
Recovery. – Recovery of the analyte was evaluated at each of the three diﬀ erent con-
centrations, 0.5, 5 and 25 ng mL–1. The recovery was calculated at time zero and a er 24 
hours. The recovery of ramipril was determined using the ratio of analytical signal from 
ﬁ ve repeats of each ramipril extract concentration compared to the signal from non-ex-
tracted methanol standards of equal concentrations.
Stability. – At time zero by each of the tested samples (ramipril in human plasma at 0.5, 
5, 25 ng mL–1) was repeated analysed ﬁ ve times by LC-Q-TOF-MS. The samples were then 
stored at 5 °C in an autosampler and analyzed again a er 24 h.
Fragmentation study
Fragmentation analysis of ramipril in a concentration of 1.5 µg mL–1 was carried out 
by the MS/MS mode with spectral parameters: mass range 50–1000 m/z, acquisition rate 1.5 
spectrum s–1 and collision energy 35 V. Other spectrometric parameters are given in Table 
I. Detailed analysis of ramipril fragmentation was carried out using the Agilent Mass-
Hunter Qualitative Analysis B.06.00 so ware.
RESULTS AND DISCUSSION
LC-Q-TOF-MS analysis
Quantitative ions for ramipril and diazepam-D5 were 417.2384 [M+H]+ and 290.1103 
[M+H:35Cl]+ respectively. The ramipril conﬁ rmational ion of highest intensity was the 
234.14886 [M-C9H13NO3]+ ion. The qualitative ion for diazepam-D5 was its isotope ion 
292.10735 [M+H:37Cl]+. Retention time for ramipril was 4.48 min, for IS 5.8 min. Fig. 1 shows 
that ramipril elutes when the intensity of matrix is relatively low. The highest intensity of 
the matrix can be seen on the chromatogram between 2 and 3.6 min and also a er 6 min. 
Due to the high speciﬁ city of detection (ﬁ ve decimal places for masses of investigated 
compounds), no interfering peaks were observed at the retention time of ramipril and IS. 
Thus it is possible to achieve high peak intensity and high sensitivity of the method, along 
with speciﬁ city.
Validation and sensitivity parameters
Linearity. – The linear concentration range is from 0.5 to 50 ng mL–1 for ramipril. The 
coeﬃ  cient of determination (R2) was > 0.999. The calibration line equation was y = 1.007888 
x – 0.012159. The lower dynamic range in comparison to triple quadrupole mass spectro-
metry is a consequence of ion saturation at the upper part of the concentration range. It 
particularly refers to the compounds that have a chloride atom in their structure. How-
ever, therapeutic concentrations of ramipril according to TIAFT (The International Asso-
ciation of Forensic Toxicologists) 1–10 ng mL–1 are within the range of calibration curve.
LLOQ is deﬁ ned as the lowest validated spike level meeting the method performance 
acceptability criteria (mean recoveries for each representative commodity in the range 
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70–120 %, with a RSD ≤ 20 %). A LLOQ of ramipril in human plasma was determined to be 
0.5 ng mL–1. Limiting values evaluation based on the signal-to-noise ratio can be applied 
to analytical methods that exhibit baseline noise. Application of the Q-TOF-MS detection 
system achives an HPLC chromatogram without baseline noise. During the extraction of 
ramipril ion (with accuracy of up to 20 ppm) the signal-to-noise was formal inﬁ nite for 
each calibration point. Such situations have already been described (23, 24).
Precision. – RSD data obtained from ﬁ ve plasma repetitive measurements of three 
spiked plasma samples (0.5, 5, 25 ng mL–1 ramipril) ranged from 3.3–8.6 %.
Recovery and stability. – The results of stability and recovery of ramipril in plasma are 
shown in Table II. At time zero, mean recovery was from 65.3 to 97.3 % whereas inter-day 
recovery ranged from 66.0 to 100.0 %. The intra-day RSD was lower than inter-day RSD at 
each concentration. As expected the highest decrease of precision was detected for the 
lowest concentration of 0.5 ng mL–1.
Fig. 1. Q-TOF-MS spectrum and extract ion chromatogram (EIC) of ramipril (X) and diazepam-D5 (Y). 
Total ion chromatogram (Z).

























l    0.5   0.68 71.3 8.6   0.63   66.0 17.1
5   4.72 65.3 3.3   4.87   70.0   3.6
25 23.92 97.3 6.1 24.55 100.0   6.2
a n = 5.
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Mass studies of the fragmentation pa ern for ramipril
The data from MSn studies (Table III) helped to propose the fragmentation pathway of 
ramipril (Fig. 2.) We conducted an MS/MS analysis of four precursor ions, m/z 417.2384, 
343.20162, 234.14886 and 156.10191. The molecular ion peak of ramipril (417.2384) fragment-
ed in MS2 into ten ions of m/z 343.20162, 234.14886, 206.11756, 160.11208, 156.10191, 134.09643, 
130.08626, 117.06988, 110.09643, 102.05495. In other MSn steps, some of which are repeated, 
we observed that there are two ways of fragment 117.06988 formation: the ﬁ rst 
343.20162117.06988 and the second 234.14886117.06988, but only one way of formation 
of 102.05495 (234.14886102.05495). Ion 343.20162 was formed when ramipril lost ethylfor-
mate while ion 234.14886 was formed during the hydrolysis of amide.
Fig. 2 shows total mass fragments of ramipril obtained in a Q-TOF-MS/MS study. Due 
to the high resolution of the spectrometer we could propose the molecular formula for 
Fig. 2. (+) ESI MS2 spectrum of ramipril [M+H]+ = 417.2384
Table III. MSn fragmentation of ramipril









343.20162, 234.14886, 206.11756, 160.11208, 156.10191, 134.09643, 
130.08626, 117.06988, 110.09643, 102.05495
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each fragment with high probability. Experimental mass for major fragments of ramipril, 
mass error in ppm (parts per million) and proposed elemental composition are shown in 
Table IV.
In the MS/MS spectrum, we observed four fragments of ramipril (234.14886, 160.11208, 
130.08626 and 117.06988) of high intensity. These fragments may be successfully employed 
as conﬁ rmative ions in Q-TOF-MS/MS analysis.
Using the obtained MS/MS spectra and deﬁ ned accurate masses we proposed the 
ramipril fragmentation pathway (Fig. 3). Fragmentation pathway of ramipril is very simi-
lar to the fragmentation pa ern for trandolapril proposed by Dendeni et al. (25). However, 
we have not observed ions such as 280 (which would be the form of 234 ion) or 252 (which 
would be the form of 206 ion). The proposed fragmentation mechanism is based on the 
hydrolysis of amide and hydrolysis of ester, like in the trandolapril fragmentation path-
way.
Table V. shows the comparison of the method presented in this paper to the results 
obtained by other authors. Three diﬀ erent techniques were used for the isolation of 
ramipril from biological material: precipitation with organic solvents, liquid-liquid extrac-
tion (LLE) and solid phase extraction (SPE). The use of SPE resulted in highest recovery 
rates (above 81 %). However, this method requires special columns and is time consuming. 
On the other hand, the recovery for methods that use only LLE with ethyl acetate was less 
than 70 %, which is also undesirable (15). In this article, we combined precipitation with 
acetonitrile and LLE with ethyl acetate, which resulted in a higher value for the recovery 
compared to the authors who used only ethyl acetate (15). Another aspect that has to be 
noted is the use of a variety of internal standards by other authors. All authors who used 
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deuterated standards or substances very similar to ramipril, trandolaprilat or enalapril, 
mostly obtained very high recoveries. Table V shows that only in this work the method 
used for ramipril determination was high resolution mass spectrometry. Aplication of Q-
TOF enabled us to achieve multiple levels of fragmentation (MSn) for the elucidation of 
ramipril structure. It has not been described in any of the cited references. Despite the fact 
that most authors used a much more sensitive technique (LC-QQQ-MS/MS), the LLOQ 
achived in method is comparable to the other papers where LLOQ was 0.1–2 ng mL–1. The 
method developed can be applied to clinical and toxicological studies.
Fig. 3. Proposed fragmentation pathway of ramipril.
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CONCLUSIONS
This paper presents validation of the UPLC-Q-TOF-MS method for determination of 
ramipril in human plasma. The proposed method was simple, speciﬁ c, precise and sensi-
tive with a minimal quantity of matrix through the use of precipitation combined with 
extraction. Despite the fact that the Q-TOF analyzer is commonly considered to be a device 
for qualitative and not for quantitative analysis because of its limited linearity, our study 
shows that it can be successfully used also for quantitative analysis in a limited range of 
concentrations. This method can be used in toxicological and reaction kinetics studies of 
ramipril.
Acknowledgements. – The authors are greatful to Agnieszka Mądro PhMD, Chair, and Depart-
ment of Gastroenterology with Endoscopic Unit, Medical University of Lublin, Poland, for providing 
the clinical material.
Table V. Comparison of methods for determination of ramipril in biological samples
Matrix Sample preparation Method Recovery / IS LOQ(ng mL–1) Ref.
Plasma 
and urine SPE (C18 Bond Elut) GC-MS –/ ramipril-D4 – (8)
Plasma SPE (C18 Bond Elut) LC-QQQ-MS/MS 84.2–87.4 % / ramipril-D3 0.1 (9)
Plasma SPE (DVBLP cartridge) LC-QQQ-MS/MS






with MeOH/0.1 M ZnSO4 
(4:1, v/v) solution
LC-QQQ-MS/MS 68.5 % /doxepin-D3 0.5 (12)
Plasma
LLE (methyl tertiary 
butyl ether : 
dichloromethane; 85:15)
LC-QQQ -MS/MS 77.7–82.9 % / carbamazepine 2 (14)
Plasma LLE (ethyl acetate) LC-QQQ-MS/MS 64.5–69.7 % / enalapril 0.1 (15)
Plasma SPE (Oasis HLB extraction cartridge) LC-QQQ-MS/MS 88.7 % / enalapril 0.5 (16)
Serum protein precipitation with MeOH LC-QQQ-MS/MS
83.4–90.7 % / 
enalapril 0.1 (17)
Plasma SPE (Oasis HLB extraction cartridge) LC-QQQ-MS/MS





protein precipitation with 
acetonitrile combined 
with LLE (ethyl acetate)
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